SMURF2 and benign prostatic hyperplasia: These include SRC proto-oncogene (SRC), Beta-Transducin Repeat Containing E3 Ubiquitin Protein Ligase (BTRC), cyclin D1 (CCND1), transcription factor activator protein-1 (AP-1), Promyelocytic leukemia protein (PML), SMAD Specific E3 Ubiquitin Protein Ligase 2 (SMURF2) which could be targeted to provide relief from voiding symptoms associated with BPH.